Rhenman & Partners Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Rhenman & Partners Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.3M	Buy	75,890 +1,860	+3%	+$325K	1.77%	17
2025 Q4	$12.6M	Sell	74,030 -21,000	-22%	-$3.22M	1.18%	33
2025 Q3	$12.5M	Sell	95,030 -14,000	-13%	-$1.68M	1.39%	30
2025 Q2	$11.6M	Sell	109,030 -15,270	-12%	-$1.66M	1.46%	27
2025 Q1	$15.4M	Sell	124,300 -21,200	-15%	-$2.77M	1.77%	24
2024 Q4	$17.9M	Buy	145,500 +52,500	+56%	+$6.19M	1.84%	21
2024 Q3	$10.4M	Sell	93,000 -21,000	-18%	-$2.3M	0.84%	40
2024 Q2	$12.2M	Sell	114,000 -32,729	-22%	-$3.6M	1.17%	32
2024 Q1	$17.7M	Buy	146,729 +23,095	+19%	+$2.83M	1.67%	24
2023 Q4	$15.2M	Sell	123,634 -20,000	-14%	-$2.5M	1.52%	24
2023 Q3	$18.6M	Sell	143,634 -1,366	-0.9%	-$182K	2%	21
2023 Q2	$18M	Sell	145,000 -5,000	-3%	-$673K	1.89%	23
2023 Q1	$21.7M	Buy	150,000 +22,000	+17%	+$3.25M	2.39%	16
2022 Q4	$20.4M	Sell	128,000 -3,500	-3%	-$513K	2.13%	17
2022 Q3	$18.9M	Sell	131,500 -28,500	-18%	-$4.33M	1.98%	20
2022 Q2	$25M	Sell	160,000 -21,976	-12%	-$3.38M	2.84%	11
2022 Q1	$28.3M	Sell	181,976 -108,024	-37%	-$15.7M	2.79%	6
2021 Q4	$37.2M	Buy	290,000 +10,000	+4%	+$1.31M	2.47%	11
2021 Q3	$36.5M	Buy	280,000 +60,000	+27%	+$9.07M	2.56%	8
2021 Q2	$39.1M	Sell	220,000 -30,000	-12%	-$5.2M	2.65%	4
2021 Q1	$41.1M	Buy	250,000 +30,000	+14%	+$4.94M	2.87%	4
2020 Q4	$36.3M	Buy	220,000 +50,000	+29%	+$7.45M	2.96%	6
2020 Q3	$24.2M	Buy	170,000 +32,968	+24%	+$4.09M	2.16%	13
2020 Q2	$15.1M	Buy	137,032 +17,032	+14%	+$1.88M	1.63%	23
2020 Q1	$12M	Buy	120,000 +19,195	+19%	+$2.48M	1.68%	21
2019 Q4	$15M	Sell	100,805 -49,195	-33%	-$6.69M	1.65%	21
2019 Q3	$19.2M	Sell	150,000 -37,171	-20%	-$4.98M	2.41%	11
2019 Q2	$26.7M	Hold	187,171	–	–	2.94%	3
2019 Q1	$26.8M	Buy	187,171 +21,353	+13%	+$2.79M	3.13%	2
2018 Q4	$20.6M	Buy	165,818 +39,496	+31%	+$5.86M	2.35%	11
2018 Q3	$21.2M	Sell	126,322 -2,114	-2%	-$364K	2.13%	12
2018 Q2	$22.1M	Sell	128,436 -20,000	-13%	-$3.27M	2.26%	14
2018 Q1	$22.4M	Buy	148,436 +15,000	+11%	+$2.2M	2.76%	5
2017 Q4	$18M	Buy	133,436 +48,436	+57%	+$6.72M	2.43%	9
2017 Q3	$12.4M	Sell	85,000 -20	-0%	-$3.02K	1.59%	23
2017 Q2	$13.2M	Buy	85,020 +24,700	+41%	+$3.78M	1.9%	17
2017 Q1	$8.75M	Buy	60,320 +9,400	+18%	+$1.22M	1.39%	29
2016 Q4	$5.55M	Sell	50,920 -9,080	-15%	-$1.01M	1.06%	35
2016 Q3	$7.29M	Sell	60,000 -10,000	-14%	-$1.35M	1.16%	29
2016 Q2	$9.89M	Buy	70,000 +40,000	+133%	+$5.9M	1.76%	19
2016 Q1	$3.92M	Sell	30,000 -12,000	-29%	-$1.49M	0.78%	49
2015 Q4	$5.9M	Sell	42,000 -4,700	-10%	-$651K	0.89%	45
2015 Q3	$6.2M	Sell	46,700 -23,300	-33%	-$4.01M	0.99%	42
2015 Q2	$12.3M	Buy	70,000 +15,000	+27%	+$2.69M	1.48%	19
2015 Q1	$9.5M	Buy	55,000 +37,600	+216%	+$6.45M	1.6%	20
2014 Q4	$2.85M	Buy	17,400 +7,400	+74%	+$1.23M	0.83%	44
2014 Q3	$1.61M	Buy	+10,000	New	+$1.54M	0.47%	85

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Rhenman & Partners Asset Management's JAZZ Position: Q1 2026 in Review

Rhenman & Partners Asset Management increased its Jazz Pharmaceuticals (JAZZ) stake by 2.5% in Q1 2026, buying an estimated $325K and bringing the position to 75,890 shares worth $14.3M. The position accounts for 1.77% of the portfolio, ranked #17.

Rhenman & Partners Asset Management first reported a position in JAZZ in Q3 2014 and has held it in 47 quarters since. The position peaked at $41.1M in Q1 2021. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Rhenman & Partners Asset Management held 75,890 shares of Jazz Pharmaceuticals worth $14.3M as of Q1 2026.
Rhenman & Partners Asset Management bought 1,860 Jazz Pharmaceuticals shares in Q1 2026, an estimated $325K.
Jazz Pharmaceuticals made up 1.77% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #17 holding.
Rhenman & Partners Asset Management first reported a position in Jazz Pharmaceuticals in Q3 2014 and has held it in 47 quarters since.
Rhenman & Partners Asset Management's Jazz Pharmaceuticals position peaked at $41.1M in Q1 2021.
571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.